☰

add clinical section

rdmorin committed 2026-01-21 15:38:53 -0800 commit d6bb692a2e59b698416ccd1951e6091f6d37b834

				XPO1.md
			
          @@ -11,7 +11,11 @@ nocite: |

           ## Experimental Evidence

          -Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a new function (NEO).[@miloudiXPO1E571KMutationModifies2020]

          +In DLBCL, mutations at the canonical hotspot (E571) have been experimentally demonstrated to cause a new function (NEO).[@miloudiXPO1E571KMutationModifies2020] 

          +

          +## Clinical Relevance

          +

          +Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) *for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.*.

           ## Relevance tier by entity

...	...	@@ -11,7 +11,11 @@ nocite: \|
11	11
12	12	## Experimental Evidence
13	13
14		-Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a new function (NEO).[@miloudiXPO1E571KMutationModifies2020]
	14	+In DLBCL, mutations at the canonical hotspot (E571) have been experimentally demonstrated to cause a new function (NEO).[@miloudiXPO1E571KMutationModifies2020]
	15	+
	16	+## Clinical Relevance
	17	+
	18	+Selinexor (XPOVIO), an inhibitor of the nuclear export activity of XPO1 protein, has received [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy..
15	19
16	20	## Relevance tier by entity
17	21